NovoCure Ltd (NVCR) concluded trading on Thursday at a closing price of $12.54, with 5.32 million shares of worth about $66.7 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -53.25% during that period and on July 24, 2025 the price saw a loss of about -24.05%. Currently the company’s common shares owned by public are about 111.80M shares, out of which, 98.78M shares are available for trading.
Stock saw a price change of -22.64% in past 5 days and over the past one month there was a price change of -26.24%. Year-to-date (YTD), NVCR shares are showing a performance of -33.58% which decreased to -57.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $14.17 but also hit the highest price of $34.13 during that period. The average intraday trading volume for NovoCure Ltd shares is 1.26 million. The stock is currently trading -26.13% below its 20-day simple moving average (SMA20), while that difference is down -27.95% for SMA50 and it goes to -37.91% lower than SMA200.
NovoCure Ltd (NASDAQ: NVCR) currently have 111.80M outstanding shares and institutions hold larger chunk of about 77.11% of that.
The stock has a current market capitalization of $1.40B and its 3Y-monthly beta is at 0.63. It has posted earnings per share of -$1.56 in the same period. It has Quick Ratio of 1.39 while making debt-to-equity ratio of 2.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVCR, volatility over the week remained 8.94% while standing at 5.36% over the month.
Stock’s fiscal year EPS is expected to drop by -1.22% while it is estimated to decrease by -6.74% in next year. EPS is likely to grow at an annualized rate of 8.18% for next 5-years, compared to annual growth of -83.87% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Ladenburg Thalmann on July 08, 2025 offering a Buy rating for the stock and assigned a target price of $30 to it. Coverage by Evercore ISI stated NovoCure Ltd (NVCR) stock as an Outperform in their note to investors on December 02, 2024, suggesting a price target of $30 for the stock. On October 16, 2024, H.C. Wainwright Upgrade their recommendations, while on November 20, 2023, JP Morgan Resumed their ratings for the stock with a price target of $15. Stock get a Neutral rating from H.C. Wainwright on August 28, 2023.
